OD-002 (SLC15A4) — IND submission
H2 2026
H2 2026: CTA filingSource filing
ODTX biotech catalysts & pipeline
ODYSSEY THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
OD-002 (SLC15A4) — NDA/BLA submission
H2
H2: File CTA for OD-002 (SLC15A4)Source filing
OD-001 (RIPK2) — Topline data
H2 2027
Both studies will be double-blind, with topline induction results expected in the second half of 2027.Source filing
OD-001 (RIPK2) — Clinical data readout
2028
Phase 2b monotherapy induction expected in H2 2027 and monotherapy maintenance results expected in 2028Source filing
OD-002 (SLC15A4) — Clinical data readout
H2 2028
Phase 1/2a Trial Initiation Expected in H1 2027 With Efficacy Readouts Expected in H2 2028Source filing